Prognostic factors are more important for overall survival (OS) than treatment outcome in patients with metastatic breast cancer (MBC).

被引：0
|
作者：
Schmid, P
Wischnewsky, M
Sezer, O
Pape, W
Possinger, K
机构：
[1] Oncol Day Clin, Paderborn, Germany
[2] Univ Bremen, Ctr Comp Technol, Bremen, Germany
[3] Humboldt Univ, Dept Hematol & Oncol, Berlin, Germany
来源：
ANNALS OF ONCOLOGY | 2000年 / 11卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
107O
引用
收藏
页码：27 / 27
页数：1
相关论文
共 50 条
  • [1] Overall survival (OS) endpoint: an incomplete evaluation of metastatic breast cancer (MBC) treatment outcome
    Raphael, Jacques
    Verma, S.
    BREAST CANCER RESEARCH AND TREATMENT, 2015, 150 (03) : 473 - 478
  • [2] Overall survival (OS) endpoint: an incomplete evaluation of metastatic breast cancer (MBC) treatment outcome
    Jacques Raphael
    S. Verma
    Breast Cancer Research and Treatment, 2015, 150 : 473 - 478
  • [3] The effect of age on overall survival (OS) in patients with metastatic breast cancer (MBC) treated with capecitabine
    Blum, J. L.
    Hu, X.
    Odom, D.
    Sherrill, B.
    Glueck, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [4] Overall survival (OS) in metastatic breast cancer (MBC): Are we using the right endpoint in the right way?
    Raphael, Jacques
    Verma, Sunil
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (26)
  • [5] Prognostic Factors Associated With Overall Survival in Breast Cancer Patients With Metastatic Spinal Disease
    Soto, Gervith Reyes
    Cacho-Diaza, Bernardo
    Bravo-Reynab, Carlos
    Guerra-Mora, Jose Raul
    Ovalles, Carlos
    Catillo-Rangel, Carlos
    Ramirez, Manuel de Jesus Encarnacion
    Montemurro, Nicola
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2023, 15 (11)
  • [6] Trastuzumab (T) Treatment Outcomes According to Concomitant Chemotherapy Regimen: Overall Survival (OS) of HER2+Metastatic Breast Cancer (MBC) Patients
    Pearson, Sallie-Anne
    Srasuebkul, Preeyaporn
    Harris, Carole
    Ward, Robyn
    Dobbins, Timothy
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2010, 19 : S187 - S187
  • [7] EFFECT OF REDUCTION OF CIRCULATING TUMOR CELLS (CTCS) ON PROGRESSION-FREE SURVIVAL (PFS) AND OVERALL SURVIVAL (OS) IN METASTATIC BREAST CANCER (MBC) PATIENTS
    Giuliano, M.
    Giordano, A.
    Handy, B. C.
    Ueno, N.
    Andreopoulou, E.
    Alvarez, R. H.
    Valero, V.
    Hortobagyi, G. N.
    Reuben, J.
    Cristofanilli, M.
    ANNALS OF ONCOLOGY, 2010, 21 : 32 - 33
  • [8] Combination or sequential single agent for the treatment of metastatic breast cancer (MBC) patients (pts). Impact of further chemotherapy (CT) in overall survival (OS) in the Alamo registry
    Lluch, A.
    Ruiz, A.
    Martin, M.
    Alba, E.
    Pastor, M.
    de la Haba, J.
    Llombart, A.
    Ramos, M.
    del Prado, P. Martinez
    Escudero, M. J.
    CANCER RESEARCH, 2009, 69 (02) : 193S - 193S
  • [9] Real-world characteristics, treatment patterns, and overall survival in patients with metastatic breast cancer (mBC) and CNS metastases
    Alvarado-Miranda, A.
    Cabrera-Galeana, P.
    Munoz-Montano, W. R.
    Lara-Medina, F.
    Bargallo-Rocha, E.
    Arrieta-Rodriguez, O.
    Perez, M.
    Porras-Reyes, F.
    Mohar-Betancourt, A.
    Gamboa, C.
    CANCER RESEARCH, 2019, 79 (04)
  • [10] Association between bisphosphonate use in metastatic breast cancer (MBC) and overall survival
    Mathew, A.
    Rosenzweig, M. Q.
    Brufsky, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (27)
12345